Therapy-induced tumor immunosurveillance involves IFN-producing killer dendritic cells

Cancer Res. 2007 Feb 1;67(3):851-3. doi: 10.1158/0008-5472.CAN-06-3766.

Abstract

A unique class of IFN-producing killer dendritic cells (IKDC) resembling natural killer cells has been defined that can recognize and lyse tumor cells through a tumor necrosis factor-related apoptosis-inducing ligand-dependent mechanism. IKDC may mediate the host-dependent antitumor activity of Gleevec/STI571 and other therapeutics that can inhibit the c-kit tyrosine kinase. IKDC represent an important new component of the innate immune system responding to cancer.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology
  • Benzamides
  • Dendritic Cells / drug effects
  • Dendritic Cells / immunology*
  • Imatinib Mesylate
  • Immunotherapy / methods
  • Interferon-gamma / biosynthesis
  • Interferon-gamma / immunology*
  • Mice
  • Neoplasms, Experimental / immunology*
  • Neoplasms, Experimental / therapy
  • Piperazines / pharmacology
  • Pyrimidines / pharmacology

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Interferon-gamma
  • Imatinib Mesylate